Skip to content

Study · Not a test of the peptide alone · 2023

1 result

Reduction of Erythema in Moderate-Severe Rosacea by a Low Molecular Weight Heparan Sulfate Analog (HSA).

George R, Gallo RL, Cohen JL, Brown M, Okeke CAV, Byrd AS

Journal of drugs in dermatology : JDD1 Jun 2023Cited by 1 (Europe PMC)

PMID37276169 (opens in a new tab)DOI10.36849/jdd.7494 (opens in a new tab)PepBankPUB-37276169
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LL-37.

  1. 01LabNot a test of LL-37 aloneIn vitro (cells)Mechanism

    In human epidermal keratinocytes in vitro, increasing heparan sulfate analog (HSA) decreased LL‑37 toxicity and IL-8 cytokine release.

    In plain wordsIn lab tests on human skin cells, a heparan sulfate analog lowered LL‑37 toxicity and IL-8 release.

    Peptide
    LL-37
    Outcome
    DecreaseLL-37 toxicity and IL-8 release in keratinocytes with heparan sulfate analog (HSA)
    Study

    humann: not reported in source

    human epidermal keratinocytes
    Outcome group
    Inflammation markers · Skin and wound

    Source sentences

    Summary
    in vitro studies using human epidermal keratinocytes showed an increase in HSA decreased LL-37 toxicity and IL-8 cytokine release.

    In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LL-37.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 12:39 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.